Fig. 1

a Absolute counts (×10⁹/L) of different B cell populations; A alemtuzumab cohort, C controls. In the alemtuzumab cohort there was significant reduction in the frequency of CD19⁺ B cells (p = 0.0041), CD19⁺CD5⁺ B cells (p = 0.0175), naïve B cells (CD19⁺CD27^-) (p = 0.0041), and CD19⁺CD24^hiCD38^hi B cells (p = 0.003). b Rheumatoid factor (RF) titres (IU) in patients with rheumatoid arthritis (n = 10) pre and post treatment with alemtuzumab. The post treatment titres are either 12 years (n = 8) or 20 years (n = 2) after alemtuzumab administration. We show a clear trend in fall in RF titres in 9/10 patients but this was not statistically significant (p = 0.084). *p <0.05, **p < 0.01